Category: Press Release

This category covers all news related Press Release

Posted on

ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLRN

NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ACELYRIN, INC. (NASDAQ: SLRN) between May 4, 2023 and September 11, 2023, both dates inclusive (the “Class Period”), of the important January 16, 2024 lead plaintiff deadline.

SO WHAT: If you purchased ACELYRIN securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the ACELYRIN class action, go to https://rosenlegal.com/submit-form/?case_id=20478 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 16, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) izokibep was less effective in treating Hidradenitis Suppurativa (“HS”) than defendants had led investors to believe; (2) accordingly, ACELYRIN overstated izokibep’s clinical and/or commercial prospects; (3) as a result, ACELYRIN also overstated the Company’s business prospects post-IPO; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the ACELYRIN class action, go to https://rosenlegal.com/submit-form/?case_id=20478 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 9012889

Posted on

ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLRN

NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ACELYRIN, INC. (NASDAQ: SLRN) between May 4, 2023 and September 11, 2023, both dates inclusive (the “Class Period”), of the important January 16, 2024 lead plaintiff deadline.

SO WHAT: If you purchased ACELYRIN securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the ACELYRIN class action, go to https://rosenlegal.com/submit-form/?case_id=20478 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 16, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) izokibep was less effective in treating Hidradenitis Suppurativa (“HS”) than defendants had led investors to believe; (2) accordingly, ACELYRIN overstated izokibep’s clinical and/or commercial prospects; (3) as a result, ACELYRIN also overstated the Company’s business prospects post-IPO; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the ACELYRIN class action, go to https://rosenlegal.com/submit-form/?case_id=20478 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 9012889

Posted on

Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline

Potential First-in-Class Novel Molecule with Novel Target In-Licensed from Collaboration with Bayer

SALT LAKE CITY, Jan. 04, 2024 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has signed an agreement with Bayer AG to in-license a new chemical entity that emerged from the companies’ fibrosis research collaboration. The compound represents a novel approach to treating fibrotic diseases with compelling early data suggesting the potential to reverse disease-related fibrotic processes, including immuno-mesenchymal dysfunction.

“Since initiating our research collaboration with Bayer in 2020, we have worked diligently to apply the power of the Recursion OS to identify and advance potential candidates in challenging areas of disease biology,” said Chris Gibson, Ph.D., Co-founder and CEO of Recursion. “We are excited to bring this asset into our internal pipeline and accelerate the compelling science behind this program while our research collaboration with Bayer focuses on precision oncology.”

Recursion applied phenotypic screening of human cells to identify small molecules that reverse the phenotypic features of disease-state fibrocyte cells into those of healthy-state cells. Leveraging the power of Recursion’s Maps of Biology and Chemistry revealed a relationship between small molecule hits and a novel target that could impact fibrotic diseases. The most promising small molecule hits were confirmed as potent inhibitors of this novel target in validation experiments, and lead optimization studies are currently ongoing.

Fibrotic diseases are a significant cause of morbidity and mortality worldwide with high unmet need for patients. One of the biggest challenges in the treatment of fibrotic diseases is the underlying complex biology and the associated difficulty in discovering disease-modifying drug targets. Recursion’s technology is uniquely suited to accelerate discoveries in these and other complex areas of disease biology.

About Recursion
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology, and chemistry to advance the future of medicine.

Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal and the San Francisco Bay Area. Learn more at www.Recursion.com, or connect on Twitter and LinkedIn.

Media Contact
Media@Recursion.com

Investor Contact
Investor@Recursion.com

Forward-Looking Statements
This document contains information that includes or is based upon “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding early and late stage discovery, preclinical, and clinical programs; licenses and collaborations; prospective products and their potential future indications and market opportunities; Recursion OS and other technologies; business and financial plans and performance; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K. All forward-looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.

GlobeNewswire Distribution ID 9012419

Posted on

New research harnesses AI and satellite imagery to reveal the expanding footprint of human activity at sea

Study reveals 75 percent of the world’s industrial fishing vessels are hidden from public view

WASHINGTON, D.C., Jan. 03, 2024 (GLOBE NEWSWIRE) — A new study published today in the journal Nature offers an unprecedented view of previously unmapped industrial use of the ocean and how it is changing.

The groundbreaking study, led by Global Fishing Watch, uses machine learning and satellite imagery to create the first global map of large vessel traffic and offshore infrastructure, finding a remarkable amount of activity that was previously “dark” to public monitoring systems.

The analysis reveals that about 75 percent of the world’s industrial fishing vessels are not publicly tracked, with much of that fishing taking place around Africa and south Asia. More than 25 percent of transport and energy vessel activity are also missing from public tracking systems.

“A new industrial revolution has been emerging in our seas undetected—until now,” said David Kroodsma, director of research and innovation at Global Fishing Watch and co-lead author of the study. “On land, we have detailed maps of almost every road and building on the planet. In contrast, growth in our ocean has been largely hidden from public view. This study helps eliminate the blind spots and shed light on the breadth and intensity of human activity at sea.”

Researchers from Global Fishing Watch, the University of Wisconsin-Madison, Duke University, UC Santa Barbara and SkyTruth analyzed 2 million gigabytes of satellite imagery spanning 2017-2021 to detect vessels and offshore infrastructure in coastal waters across six continents where more than three-quarters of industrial activity is concentrated.

By synthesizing GPS data with five years of radar and optical imagery, the researchers were able to identify vessels that failed to broadcast their positions. Using machine learning, they then concluded which of those vessels were likely engaged in fishing activity.

“Historically, vessel activity has been poorly documented, limiting our understanding of how the world’s largest public resource—the ocean—is being used,” said co-lead author Fernando Paolo, senior machine learning engineer at Global Fishing Watch. “By combining space technology with state-of-the-art machine learning, we mapped undisclosed industrial activity at sea on a scale never done before.”

While not all boats are legally required to broadcast their position, vessels absent from public monitoring systems, often termed “dark fleets,” pose major challenges for protecting and managing natural resources. Researchers found numerous dark fishing vessels inside many marine protected areas, and a high concentration of vessels in many countries’ waters that previously showed little-to-no vessel activity by public monitoring systems.

“Publicly available data wrongly suggests that Asia and Europe have similar amounts of fishing within their borders, but our mapping reveals that Asia dominates—for every 10 fishing vessels we found on the water, seven were in Asia while only one was in Europe,” said co-author Jennifer Raynor, assistant professor of natural resource economics at the University of Wisconsin-Madison. “By revealing dark vessels, we have created the most comprehensive public picture of global industrial fishing available.”

The study also shows how human activity in the ocean is changing. Coinciding with the COVID-19 pandemic, fishing activity dropped globally by about 12 percent, with an 8 percent decline in China and a 14 percent drop elsewhere. In contrast, transport and energy vessel activity remained stable.

Offshore energy development surged during the study period. Oil structures increased by 16 percent, while wind turbines more than doubled. By 2021, turbines outnumbered oil platforms. China’s offshore wind energy had the most striking growth, increasing ninefold from 2017 to 2021.

“The footprint of the Anthropocene is no longer limited to terra firma,” said co-author Patrick Halpin, professor of marine geospatial ecology at Duke University. “Having a more complete view of ocean industrialization allows us to see new growth in offshore wind, aquaculture and mining that is rapidly being added to established industrial fishing, shipping and oil and gas activities. Our work reveals that the global ocean is a busy, crowded and complex industrial workspace of the growing blue economy.”

The study highlights the potential of this new technology to tackle climate change. Mapping all vessel traffic will improve estimates of greenhouse gas emissions at sea, while maps of infrastructure can inform wind development or aid in tracking marine degradation caused by oil exploration.

“Identifying offshore infrastructure is critical for understanding offshore energy development impacts and trends, and is crucial data for our work to detect marine pollution events and hold responsible parties to account,” said co-author Christian Thomas, a geospatial engineer at SkyTruth.  

The open data and technology used in the study can help governments, researchers and civil society to identify hotspots of potentially illegal activity, determine where industrial fishing vessels may be encroaching on artisanal fishing grounds, or simply better understand vessel traffic in their waters.

“Previously, this type of satellite monitoring was only available to those who could pay for it. Now it is freely available to all nations,” concluded Kroodsma. “This study marks the beginning of a new era in ocean management and transparency.”

The study was made possible thanks to the generous support of Bloomberg Philanthropies, National Geographic Pristine Seas and Oceankind, and our technology partner, Google. As an awardee of The Audacious Project, a collaborative funding initiative that is catalyzing social impact on a grand scale, Global Fishing Watch is able to further the application of this innovative work.

Notes to the editor:

  • Download supporting data visualizations and figures from the paper here: Media kit
  • Download the data at: https://globalfishingwatch.org/datasets-and-code
  • Data providers: The co-authors of the study wish to acknowledge the contribution from the following technology and data providers; AIS: Spire, ORBCOMM; Radar and optical imagery: European Space Agency (ESA); and Computing resources: Google / Earth Engine.

Global Fishing Watch is an international nonprofit organization dedicated to advancing ocean governance through increased transparency of human activity at sea. By creating and publicly sharing map visualizations, data and analysis tools, we aim to enable scientific research and transform the way our ocean is managed. We believe human activity at sea should be public knowledge in order to safeguard the global ocean for the common good of all.

Attachments

Sarah Bladen
Global Fishing Watch
+44 79 20333832
sarah.bladen@globalfishingwatch.org

Lisa Tossey
Global Fishing Watch
+1 302 4486638
lisa.tossey@globalfishingwatch.org

GlobeNewswire Distribution ID 9012061

Posted on

Enovis Completes Acquisition of LimaCorporate S.p.A

WILMINGTON, Del., Jan. 03, 2024 (GLOBE NEWSWIRE) — Enovis™ Corporation (NYSE: ENOV, “Enovis” or the “Company”) an innovation-driven, medical technology growth company, today announced that it closed the acquisition of LimaCorporate S.p.A. (“Lima”), a privately held global orthopedic leader focused on restoring motion through an innovative portfolio of implant solutions.

Lima strengthens Enovis’ position in the global orthopedic reconstruction market with a complementary portfolio of proven surgical solutions and technologies, which will accelerate global growth and margin expansion. In addition, Lima’s portfolio includes 3D printed Trabecular Titanium implants and a comprehensive revision offering in shoulders, which will further strengthen the Company’s position in the fast-growing extremities market.

“We are excited to welcome Lima’s talented team to Enovis. The combination brings Enovis’ recon segment to $1 billion in revenues and creates a fast-growing innovator in the global orthopedic reconstruction market. This is another great example of how we use strategic acquisitions to accelerate our growth, add great technologies and talent to our company, and drive compounding value for our shareholders,” said Matt Trerotola, Chair, and Chief Executive Officer of Enovis.

About Enovis Corporation
Enovis Corporation (NYSE: ENOV) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent, and innovation, the Company’s extensive range of products, services, and integrated technologies fuels active lifestyles in orthopedics and beyond. The Company’s shares of common stock are listed in the United States on the New York Stock Exchange under the symbol ENOV. For more information about Enovis, please visit www.enovis.com

Forward-Looking Statements
This press release includes forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements regarding the Company’s plans, objectives, expectations and intentions and other statements that are not historical or current fact. Forward-looking statements are based on the Company’s current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause the Company’s results to differ materially from current expectations include, but are not limited to, risks and uncertainties regarding the Company’s and Lima’s respective businesses, and actual results may differ materially. These risks and uncertainties include, but are not limited to, the effects of the acquisition on the Company’s and Lima’s operations, including on the combined company’s future financial condition and performance, operating results, strategy and plans, including anticipated tax treatment, unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, losses, future prospects, and business and management strategies for the management, expansion and growth of the new combined company’s operations; the potential impact of the consummation of the acquisition on relationships with customers, suppliers and other third parties; and the other factors detailed in the Company’s reports filed with the U.S. Securities and Exchange Commission (the “SEC”), including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption “Risk Factors,” as well as the other risks discussed in the Company’s filings with the SEC. In addition, these statements are based on assumptions that are subject to change. This press release speaks only as of the date hereof. The Company disclaims any duty to update the information herein.

Investor Relations Contact
Kyle Rose
Vice President, Investor Relations
Enovis Corporation
+1-917-734-7450
investorrelations@enovis.com

Media Contact
Katie Sweet
Vice President, Corporate Communications
Enovis Corporation
Katie.sweet@enovis.com

GlobeNewswire Distribution ID 9011517

Posted on

Sweegen Triumphs in Federal Court Appeal, Securing Victory Against PureCircle

Foothill Ranch, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) — Sweegen, the global leader in pioneering wellness ingredient and taste modulation technologies, announced a landmark victory in the U.S. Court of Appeals for the Federal Circuit, which has sided with Sweegen and affirmed the invalidation of PureCircle’s patents covering the highly sought-after stevia sweetener Rebaudioside M (Reb M).

Sweegen is the primary producer of non-GMO Reb M originating from the stevia leaf, made with a proprietary clean bioconversion method. This appellate victory further solidifies Sweegen’s technological leadership position in the stevia sweetener industry at large.

Reb M, a highly coveted steviol glycoside molecule, plays a crucial role in the global production of stevia sweeteners. This Federal Circuit decision removes any lingering doubt that Consumer Packaged Goods (CPG) customers may be encumbered by PureCircle’s patents for using Sweegen’s Reb M.

“As one of the staunchest stewards of proprietary technologies in wellness ingredients, Sweegen has actively defended its intellectual property rights while upholding a commitment to respecting the rights of others,” stated Sweegen’s CEO Steven Chen. “Throughout this litigation, we consistently asserted the invalidity of PureCircle’s patents, considering their case against Sweegen as baseless and spurious. This triumph in the U.S. Court of Appeals serves to highlight Sweegen’s dedication to principled innovation and fair competition within the industry.”

In May 2022, Sweegen secured a groundbreaking summary judgment, declaring PureCircle’s asserted patents related to the production of Reb M as invalid. The affirmation today of this judgment by the U.S. Court of Appeals for the Federal Circuit solidifies Sweegen’s position and removes any impediments that PureCircle’s patents may have posed for producers in the United States. Specifically, the federal court’s Opinion confirmed the district court’s decision that certain claims in the patents were found invalid due to a lack of written description. Additionally, it determined that a specific claim in one of the patents is unpatentable under 35 U.S.C. § 101.

“Sweegen’s commitment to innovation, excellence, and fair competition has been reaffirmed through the successful appeal process,” said Chen. “This victory not only strengthens Sweegen’s position in the market but also contributes to the broader landscape of the stevia sweetener industry. Sweegen is positioned to lead the charge in shaping a landscape of limitless possibilities, delivering unparalleled sweetness to consumers and driving positive change on a global scale.”

Sweegen remains committed to driving positive change within the sweetener industry and will continue to invest in research and development to deliver cutting-edge solutions to its global customer base.

In Nov. 2023, Sweegen announced it was addressing the pressing issue of mislabeling within the stevia industry, specifically concerning Reb M stevia sold under intentionally false claims. Through independent testing, the company has determined that certain third-party Reb M products sold to food and beverage companies under label claims of “Reb-M 95%,” “Bioconversion Reb-M 95%,” or “Stevia (Organic) Extract Reb-M 95%” are not made through extraction or bioconversion. Sweegen continues its investigation into the adulterated Reb M.

The U.S. Court of Appeals for the Federal Circuit case is Pure Circle Inc., et al v. Sweegen, et al., case number appeal number 2022-1946.

This Appeal is from the first summary judgment case PureCircle USA Inc., et al. v. Sweegen, Inc., et al., case number 8:18-CV-01679-JVS-JDE, in the United States District Court, Central District of California, Southern Division, Judge James V. Selna. Sweegen was represented at both the US District Court and the Federal Circuit by John Christopher “JC” Rozendaal, Dennies Varughese, Michael E. Joffre, Anna G. Phillips, and Sasha Rao of the law firm Sterne Kessler Goldstein & Fox PLLC.

About Sweegen
Sweegen provides sweet taste solutions for food and beverage manufacturers around the world.

We are on a mission to reduce the sugar and artificial sweeteners in our global diet.  Partnering with customers, we create delicious zero-sugar products that consumers love.  With the best modern sweeteners in our portfolio, such as Bestevia® Rebs B, D, E, I, M, and N, and brazzein, along with our deep knowledge of flavor taste modulators and texturants, Sweegen delivers market-leading solutions that customers want, and consumers prefer. Well. Into the Future.

For more information, please contact info@sweegen.com and visit Sweegen’s website, www.sweegen.com.

Attachment

Ana Capretz, Head of Public Relations and Communications
Sweegen
+1.949.709.0583
ana.capretz@sweegen.com

GlobeNewswire Distribution ID 9011707